In our recent review published in Angiology, we appraised the evidence for the use of novel anticoagulants for prevention of thromboembolic events among patients with atrial fibrillation (AF). 1 Further to the relevant megatrials of dabigatran (RELY: Randomized Evaluation of Long-Term Anticoagulation Therapy) and rivaroxaban (ROCKET-AF: Rivaroxaban Once daily oral direct Factor Xa inhibition Compared with vitamin K antagonist for the prevention of stroke and Embolism Trial in Atrial Fibrillation) that were commented in detail, 2,3 the ARIS-TOTLE trial was very recently published. 4 This double-blind, double-dummy, randomized trial evaluated the efficacy and safety of apixaban, a novel direct inhibitor of factor Xa, for the prevention of stroke or systemic embolism in patients with AF. The study population included more than 18 000 patients with at least 1 stroke risk factor who were randomized to receive either standard treatment with warfarin (target international normalized ratio [INR] of 2.0-3.0) or apixaban 5 mg twice daily with a predefined dose reduction (2.5 mg twice daily) in patients anticipated to have a higher drug exposure (presence of 2 or more of the following criteria: age 80 years, weight 60 kg, and serum creatinine 1.5 mg/dL).
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Based on the primary intention-to-treat analysis and after a median follow-up period of 1.8 years, apixaban was superior to warfarin in reducing the rate of stroke or systemic embolism (hazard ratio [HR]: 0.79; 95% confidence interval [CI]: 0.66-0.95, P ¼ .01). The enhanced efficacy performance was accompanied by a significant reduction in the rate of major bleeding (HR: 0.69; 95% CI: 0.60-0.80, P < .001) and a significantly lower all-cause mortality (HR: 0.89; 95% CI: 0.80-0.99, P ¼ .047). The main study results showed that apixaban presents both enhanced efficacy and safety and also reduces allcause mortality compared with warfarin. However, several issues regarding the results and the methodology of the ARIS-TOTLE trial should be taken into consideration.
The primary efficacy end point in the ARISTOTLE trial, as well as in the RELY and the ROCKET-AF trial, was a composite end point of systemic thromboembolism, ischemic stroke, and hemorrhagic stroke. Therefore, the combined efficacy measure is also influenced by the occurrence of hemorrhagic stroke, an individual outcome variable that reflects patient safety (ie, bleeding event). Based on the results of ARISTOTLE, the significant reduction in the primary efficacy end point was driven by the lower rate of hemorrhagic stroke, while there was no significant difference in the rate of ischemic strokes between the 2 groups. Therefore, apixaban exhibits equivalent efficacy in prevention of ischemic thromboembolic events and superior safety in prevention of both intracranial and extracranial bleeding events compared with warfarin. On the other hand, we should keep in mind that the classification of a stroke as either hemorrhagic or ischemic may prove to be challenging in every day clinical practice, while there is always the likelihood of hemorrhagic transformation of an ischemic stroke.
An issue that should be kept in mind while considering the findings of similar trials is that statistical significance is not synonymous with clinical significance. Hazard ratio is an indicator of the magnitude of an effect and consequently of its clinical significance. On the other hand, the P value expresses the statistical significance of a finding and denotes the likelihood that the study result is due to chance. The larger the sample size, the higher the likelihood that a small treatment effect will reach statistical significance.
The mortality reduction in the 3 trials of novel anticoagulants is quite comparable. In the ARISTOTLE trial, the rate of all-cause death was 11% lower in the apixaban compared with the warfarin group, reaching statistical significance. On the other hand, the respective rate reduction (magnitude of effect) caused by rivaroxaban and the high dabigatran dose was 15% (on treatment analysis, P ¼ .07) and 12% (P ¼ .051), respectively. Therefore, treatment effects of similar magnitude have different P values, largely reflecting variations in the sample size and in the methodology among the 3 trials. The similar survival data in these 3 large-scale trials are indicative of a consistent treatment effect despite the subtle differences in P values, creating a robust body of evidence in favor of novel anticoagulants.
Learning is a process of trial and error
One of the reasons why apixaban had better results than rivaroxaban is that methodological caveats that seem to have underestimated the magnitude of benefit gained by rivaroxaban in the ROCKET-AF were avoided during the design of the ARISTOTLE trial:
Based on the ARISTOTLE study design, the primary analysis included all efficacy end points from randomization until a predefined cutoff date when 75% of the patients were still taking apixaban. In this way, the majority of patients randomized to the apixaban group were actually ''on treatment'' when the primary end point evaluation period was completed. Therefore, the difference between on treatment (those actually taking the study drug) and intention to treat analysis (total of patients assigned to take the drug on randomization) was minimized, avoiding underestimation of apixaban's beneficial effect and increasing the likelihood of demonstrating efficacy superiority in the intention-totreat analysis. In contrast, in the ROCKET-AF, there was a difference of almost 4 months between median follow-up and median treatment exposure, thus increasing the gap between on-treatment and intention-to-treat analysis and underestimating the true benefit of rivaroxaban. The ARISTOTLE design provided an algorithm to guide physicians in case of temporary discontinuation of study drug during the study period (eg, in case of interventional procedure) without affecting concealment of the group assignment. Furthermore, a bridging strategy was available to support safe transition to open-label warfarin, thus avoiding intervals of suboptimal anticoagulation. This pitfall was not averted in the ROCKET-AF and resulted in a clustering of primary events in the rivaroxaban group upon termination of randomized treatment and subsequent transition to other appropriate therapy.
In the ARISTOTLE trial, an aggressive INR control program was implemented aiming to maximize the quality level of anticoagulant treatment in the warfarin arm. The mean time to therapeutic range (TTR), calculated using the Rosendaal method (days within therapeutic INR range [2.0-3.0] divided by total number of days under anticoagulation treatment), was 62.2% which was higher than the 55% achieved in the ROCKET-AF study and similar to the 64% achieved in the RELY trial. However, differences in the TTR achieved are multifactorial in etiology and are closely related to the characteristics of the patient population (older age and more comorbidities in the ROCKET-AF trial) and the geographical distribution of the recruiting centers.
In conclusion, ARISTOTLE provides sufficient evidence, supporting the safety and efficacy of apixaban compared with warfarin. From a clinical perspective, these findings are expected to extend the available therapeutic options, further establishing the role of novel anticoagulants for thromboprophylaxis in patients with AF.
